Recent Updates
Recently added Catalysts

Biotech Earnings Calendar

Our Biotech Earnings Calendar provides detailed earnings and forecasted estimates for covered biotech companies, featuring current EPS for informed investment decisions.
November 2026calender-logo
Sun
Mon
Tue
Wed
Thu
Fri
Sat
1
2

+35 More

9+
3

+54 More

9+
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

+8 More

9+
19

+2 More

3
20
21
22
1
23

+1 More

2
24

+5 More

6
25
1
26
1
27
28
29
30
1
2
3
4
5
: 2026-11-03
Previous EPS

: 0.29

Estimated EPS:

: -0.01

: 2026-11-03
Previous EPS

: -0.09

: 2026-11-03
Previous EPS

: -0.07

: 2026-11-03
Previous EPS

: 1.75

: 2026-11-03
Previous EPS

: -0.63

Estimated EPS:

: -0.11

Description
: Drug: Anaphylm (dibutepinephrine) sublingual film (AQST-109). Indication: Type I allergic reactions, including anaphylaxis. Timeline: March 16, 2027. FDA accepted Aquestive's resubmission of the Anaphylm NDA as complete, classified it as a Class 2 response, and assigned a PDUFA goal action date of March 16, 2027 for Anaphylm (dibutepinephrine) sublingual film for Type I allergic reactions, including anaphylaxis.
: 2026-11-03
Previous EPS

: -0.31

Estimated EPS:

: -0.22

Description
: Drug: icovamenib (COVALENT-211). Indication: insulin-deficient type 2 diabetes (T2D) patients not achieving glycemic targets despite antihyperglycemic medications. Timeline: first quarter of 2027. Topline Week 26 primary endpoint results from the randomized, double-blinded, placebo-controlled Phase II COVALENT-211 trial evaluating icovamenib as add-on therapy in insulin-deficient T2D patients on antihyperglycemic medications are anticipated in the first quarter of 2027.
: 2026-11-03
Previous EPS

: -2.8

Estimated EPS:

: -0.81

Description
: Drug: IMCIVREE (setmelanotide). Indication: acquired hypothalamic obesity. Timeline: November 14-17, 2026. Five presentations accepted at ObesityWeek 2026 (Nov 14-17) include final Phase 3 trial results, two-year Phase 3 results, TRANSCEND patient-reported outcomes, and weight category improvement analyses for setmelanotide (IMCIVREE) in acquired hypothalamic obesity.
: 2026-11-03
Previous EPS

: 0

: 2026-11-03
Previous EPS

: 0.5

Estimated EPS:

: 3.01

: 2026-11-03
Previous EPS

: -14.24

Estimated EPS:

: -0.22

Description
: Drug: TP-04. Indication: ocular rosacea. Timeline: first half of 2027. TP-04 Phase 2 Kore trial for the potential treatment of ocular rosacea is progressing, with topline data explicitly expected in the first half of 2027, per the company announcement.
: 2026-11-03
Previous EPS

: 0.38

Estimated EPS:

: 0.22

: 2026-11-03
Previous EPS

: -1.15

Estimated EPS:

: 0.43

: 2026-11-03
Previous EPS

: 9.88

: 2026-11-03
Previous EPS

: 1.5

Estimated EPS:

: 0.01

Description
: Drug: miricorilant. Indication: Metabolic Dysfunction-Associated Steatohepatitis (MASH). Timeline: Year-end 2026. Enrollment will complete in the coming weeks with first results expected by the end of next year.
: 2026-11-03
Previous EPS

: -2.28

Estimated EPS:

: -0.48

Description
: Drug: OCS-01. Indication: Diabetic macular edema (DME). Timeline: Q4 2026. Oculis may submit an NDA for OCS-01 for diabetic macular edema in Q4 2026 following topline data readout from the Phase 3 DIAMOND program, per company statement.
: 2026-11-03
Previous EPS

: -2.46

Estimated EPS:

: -0.64

Description
: BEACH301 Phase 2 data readout in achondroplasia patients
: 2026-11-03
Previous EPS

: -1.61

Estimated EPS:

: 0.16

: 2026-11-03
Previous EPS

: 0

Estimated EPS:

: -0.01

Description
: Drug: ALKS 7290. Indication: Adults with attention-deficit hyperactivity disorder (ADHD). Timeline: 2027. Phase 2 study of ALKS 7290 in adults with ADHD is enrolling; data expected in 2027.
: 2026-11-03
Previous EPS

: -13.85

Estimated EPS:

: -0.76

Description
: Drug: Volixibat. Indication: Primary sclerosing cholangitis (PSC) with cholestatic pruritus. Timeline: Thursday, November 5, 2026, 12:00-1:00 p.m. MT. Poster presenting VISTAS Phase 2b data showing improvements in cholestatic pruritus across multiple measures and baseline pruritus severity with volixibat in PSC patients will be presented at AASLD The Liver Meeting 2026 on November 5, 2026.
: 2026-11-03
Previous EPS

: -1.27

: 2026-11-03
Previous EPS

: -5.14

Estimated EPS:

: -1.22

Description
: Drug: UX701 (rivunatpagene miziparvovec). Indication: Wilson disease. Timeline: 2026. Enrollment is complete for the fourth cohort in the dose-finding stage of the pivotal Cyprus2+ study of UX701 for Wilson disease; data from this stage are expected in 2026.
: 2026-11-03
Previous EPS

: 1.31

Estimated EPS:

: 0.11

Description
: Drug: MIPLYFFA (arimoclomol). Indication: Niemann-Pick disease type C, infants less than 24 months of age. Timeline: Q1 2027. Zevra anticipates filing a supplemental New Drug Application (sNDA) for MIPLYFFA (arimoclomol) for infants less than 24 months of age with Niemann-Pick disease type C in Q1 2027 following pediatric data publication and an FDA meeting.
: 2026-11-03
Previous EPS

: 5.96

: 2026-11-03
Previous EPS

: 1.81

Estimated EPS:

: 0.47

: 2026-11-03
Previous EPS

: -2.35

Estimated EPS:

: -0.6

: 2026-11-03
Previous EPS

: -20.45

Estimated EPS:

: -0.12

Description
: Company and investor-materials indicate seralutinib is being developed for PH‑ILD in addition to PAH; analysts and investor presentations reference an anticipated Phase 3 registrational program (SERANATA or equivalent) timeline that could generate data or program-level catalysts in 2026 (timing presented at program level rather than a specific trial readout date).
: 2026-11-03
Previous EPS

: -0.22

Estimated EPS:

: -0.03

Description
: Drug: IBSRELA (tenapanor). Indication: chronic idiopathic constipation (CIC) in adults. Timeline: second half of 2027. ACCEL (ten-03-301) is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial assessing the safety and efficacy of IBSRELA (tenapanor) administered twice daily for 26 weeks in ~700 adults with CIC; enrollment is expected throughout 2026 and topline data are expected to be read out in the second half of 2027.
: 2026-11-03
Previous EPS

: -2.96

Estimated EPS:

: -2.3

: 2026-11-03
Previous EPS

: 0.71

Estimated EPS:

: 0.68

: 2026-11-03
Previous EPS

: -1.88

Estimated EPS:

: -0.39

Description
: Drug: COMP360 psilocybin. Indication: Treatment-Resistant Depression (TRD). Timeline: November 5-8, 2026. Compass will present encore COMP360 data at the NEI Fall Congress in Colorado Springs (November 5-8, 2026), including efficacy and safety results and demographic/clinical characteristics from two pivotal Phase 3, double-blind, randomized, controlled TRD studies.
: 2026-11-03
Previous EPS

: 0.6

Estimated EPS:

: 0.15

: 2026-11-03
Previous EPS

: 0.61

Estimated EPS:

: 0.24

: 2026-11-03
Previous EPS

: -2.98

: 2026-11-03
Previous EPS

: 0.47

: 2026-11-03
Previous EPS

: -1.77

Estimated EPS:

: -0.41

: 2026-11-03
Previous EPS

: -1.96

Estimated EPS:

: -0.59

Description
: Drug: DNL593 (PTV:PGRN). Indication: FTD-GRN (frontotemporal dementia-granulin). Timeline: by the end of 2026. Denali will report results from its ongoing Phase 1/2 study of DNL593 (PTV:PGRN) for FTD-GRN, including biomarker results. Enrollment is completed with 40 participants; Denali regained full control of DNL593 and expects data by the end of 2026.
: 2026-11-03
Previous EPS

: 2.27

Estimated EPS:

: 1.22

: 2026-11-03
Previous EPS

: -5.87

Estimated EPS:

: -2.43

Description
: Drug: T-Pam1. Indication: Breast cancer. Timeline: late 2026. T-Pam1 in breast cancer (BC) is reported as Phase 3 and fully enrolled, with interim data expected in late 2026 according to the presentation.
: 2026-11-03
Previous EPS

: -5.38

Estimated EPS:

: -0.01

: 2026-11-03
Previous EPS

: 2.54

: 2026-11-03
Previous EPS

: -9.35

Estimated EPS:

: -5.5

: 2026-11-03
Previous EPS

: -1.01

Estimated EPS:

: -0.76

Description
: Drug: PBGENE-HBV. Indication: chronic hepatitis B. Timeline: November 5, 2026. Embargoed abstract data from the ELIMINATE-B trial for PBGENE-HBV will become public on Thursday, November 5, 2026.
: 2026-11-03
Previous EPS

: 17.36

Estimated EPS:

: 5.59

Description
: Drug: UPLIZNA (inebilizumab-cdon). Indication: IgG4-related disease. Timeline: 2026-11-08. Amgen will present Phase 3 MITIGATE open-label extension data describing long-term safety profile and sustained efficacy of UPLIZNA in IgG4-related disease, including primary Year 1 open-label period results at ACR Convergence on November 8, 2026.
: 2026-11-03
Previous EPS

: -5.78

Estimated EPS:

: -0.04

: 2026-11-03
Previous EPS

: 1.09

Estimated EPS:

: 0.52

: 2026-11-03
Previous EPS

: -8.95

Estimated EPS:

: -1.91

Description
: Drug: LNCB74 (B7-H4 ADC). Indication: Advanced solid tumors, breast and gynecological cancers, adenoid cystic carcinoma type 1. Timeline: second half of 2026. NextCure plans a trial progress update for the ongoing open-label Phase 1 dose escalation study (NCT06774963), prioritizing patients with high B7-H4 expression in breast and gynecologic cancers and adenoid cystic carcinoma type 1, in the second half of 2026.
: 2026-11-03
Previous EPS

: -2.03

Estimated EPS:

: -0.3

Description
: Data from a Phase 2 study evaluating TPST-1495 in patients with FAP is expected to be announced in 2026.
: 2026-11-03
: 2026-11-03
Previous EPS

: -0.15

Estimated EPS:

: -0.4

Description
: Drug: ARV-6723. Indication: Checkpoint-resistant tumor models / immuno-oncology (preclinical). Timeline: Nov. 4-8, 2026. Arvinas will present new preclinical data for ARV-6723 (oral PROTAC HPK1 degrader) demonstrating superior activity and anti-tumor responses versus immune checkpoint inhibitors in checkpoint-resistant models at the Society for Immunotherapy of Cancer Annual Meeting (Nov. 4-8, 2026).
: 2026-11-03
Description
: Drug: izicopan. Indication: ANCA-associated vasculitis (AAV) - randomized, placebo-controlled renal vasculitis study. Timeline: 2028. InflaRx plans a randomized, placebo-controlled Phase 2 izicopan study in AAV patients with renal involvement (site initiation early 2027); the company anticipates first Phase 2 data readouts from its AAV program in 2028.
: 2026-11-03
Previous EPS

: -0.79

Estimated EPS:

: -0.18

Description
: Drug: Mavorixafor. Indication: Primary Chronic Neutropenia (PCN). Timeline: Q1 2028. Topline data from the ongoing pivotal Phase 3 4WARD study in Primary Chronic Neutropenia (PCN) expected in Q1 2028, as stated in the investor presentation.
: 2026-11-03
Previous EPS

: -6.69

Estimated EPS:

: -2.38

Description
: Drug: Rezdiffra (resmetirom). Indication: MASH (NASH outcomes). Timeline: late 2027. Madrigal states its ongoing MAESTRO-NASH OUTCOMES trial for Rezdiffra is on track and that data are expected late 2027, positioning the program to deliver a therapy for advanced-stage MASH.
: 2026-11-03
Previous EPS

: 3.81

: 2026-11-03
Previous EPS

: -1.9

Estimated EPS:

: -0.47

: 2026-11-03
Previous EPS

: -0.33

Estimated EPS:

: 0.08

Description
: Drug: Z-1018. Indication: Shingles (prevention in adults aged 50 years and older). Timeline: in the second half of 2026. Dynavax expects to report 12-month follow-up data for Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 trial of Z-1018, which demonstrated favorable tolerability and robust immune responses versus Shingrix, in the second half of 2026.
: 2026-11-02
Previous EPS

: 16.31

Estimated EPS:

: 0.21

Description
: Selection of the recommended Phase 2 dose following conclusion of the dose expansion phase of the ongoing open-label Phase 1b study evaluating safety, tolerability, pharmacokinetics and preliminary efficacy (NCT05308264). Up to 40 patients randomized to 500 mg once or twice daily.
: 2026-11-02
Previous EPS

: -2.52

: 2026-11-02
Previous EPS

: -1.42

Estimated EPS:

: -0.43

Description
: Drug: VS-7375. Indication: KRAS G12D-mutated solid tumors. Timeline: 2H 2026. Verastem plans to report an additional update on the TARGET-D 101 Phase 1/2 trial of VS-7375, including monotherapy and combination data, with a scheduled update in 2H 2026 to inform registration-directed strategies.
: 2026-11-02
Previous EPS

: -0.15

: 2026-11-02
Previous EPS

: -0.57

Description
: Drug: remibetadex (Trappsol® Cyclo™). Indication: treatment of the neurovisceral manifestations of Niemann-Pick Disease Type C in adult and pediatric patients from birth. Timeline: Within 60 days of receiving the application. Within 60 days of receiving Cyclo Therapeutics' NDA for remibetadex, the FDA will determine whether the application is filed and, if filed, whether Priority Review will be granted.
: 2026-11-02
Previous EPS

: 2.07

: 2026-11-02
Previous EPS

: -0.3

Estimated EPS:

: -0.15

: 2026-11-02
Previous EPS

: -0.58

Estimated EPS:

: -0.28

Description
: Drug: WTX-124. Indication: relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors. Timeline: 2026-11-07. Oral presentation of a Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124, alone or in combination with pembrolizumab, in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors at SITC 2026 on November 7, 2026.
: 2026-11-02
Previous EPS

: 3.48

Estimated EPS:

: -0.24

: 2026-11-02
Previous EPS

: 0.67

: 2026-11-02
Previous EPS

: -0.32

Estimated EPS:

: -0.11

: 2026-11-02
Previous EPS

: 7.6

Estimated EPS:

: 1.79

Description
: Drug: KB707 (OPAL-1 intratumoral). Indication: Gorlin syndrome (basal cell carcinoma). Timeline: later this year. Krystal has enrolled three Gorlin syndrome patients in OPAL-1 (Phase 1/2) and expects to provide an interim clinical update on these patients and outline potential development plans later this year (2026).
: 2026-11-02
Previous EPS

: -2.99

Estimated EPS:

: -0.84

Description
: Drug: Solriamfetol. Indication: Binge eating disorder. Timeline: 1Q 2027. ENGAGE is a Phase 3 randomized, double-blind, placebo-controlled, multicenter trial evaluating solriamfetol in binge eating disorder; target enrollment has been reached and the company anticipates topline results in 1Q 2027.
: 2026-11-02
Previous EPS

: 1.71

Estimated EPS:

: 0.41

: 2026-11-02
Previous EPS

: -5.07

Estimated EPS:

: -0.09

: 2026-11-02
Previous EPS

: 6.94

Estimated EPS:

: 1.57

Description
: Drug: direclidine. Indication: schizophrenia. Timeline: 2027. Direclidine, an M4 muscarinic agonist being developed for psychiatric disorders including schizophrenia, has ongoing Phase 3 studies with topline Phase 3 data expected in 2027.
: 2026-11-02
Previous EPS

: 7.86

: 2026-11-02
Previous EPS

: 3.21

Estimated EPS:

: 6.17

Description
: Drug: JZP3507 (formerly ONC206). Indication: H3 G34-mutant glioma. Timeline: November 12-15, 2026. Oral presentation of new preclinical findings characterizing JZP3507's anti-cancer activity and ClpP-dependent mechanism in H3 G34-mutant glioma at the 2026 Society for Neuro-Oncology Annual Meeting, November 12-15, 2026 in Philadelphia.
: 2026-11-02
Previous EPS

: -2.33

Estimated EPS:

: -0.48

Description
: Drug: Revuforj (revumenib) - SAVE. Indication: NPM1m, KMT2Ar, or NUP98-rearranged (NUP98r) AML. Timeline: fourth quarter of 2026. Company expects to present frontline SAVE trial data of the all-oral revumenib, decitabine/cedazuridine, and venetoclax combination in NPM1m, KMT2Ar, or NUP98r AML in the fourth quarter of 2026.
: 2026-11-02
Previous EPS

: -0.76

Estimated EPS:

: -0.24

Description
: Drug: REC-4881 (MEK1/2 inhibitor). Indication: Familial Adenomatous Polyposis (FAP). Timeline: Monday November 2, 2026; 13:30 - 15:00 MST. Additional Phase 1b/2 safety and efficacy data for REC-4881 in familial adenomatous polyposis (FAP) from the TUPELO trial, contextualized with real-world registry data, will be presented at the CGA-IGC Annual Meeting Presidential Plenary on November 2, 2026.
: 2026-11-02
Previous EPS

: -9.91

Description
: Drug: selinexor. Indication: multiple myeloma. Timeline: second half of 2026. Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026.
: 2026-11-02
Previous EPS

: -3.23

Estimated EPS:

: -0.75

Description
: Drug: zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251). Indication: Duchenne muscular dystrophy amenable to exon 51 skipping. Timeline: January 21, 2027. FDA accepted for review the BLA for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) and granted Priority Review, assigning a PDUFA target action date of January 21, 2027.
: 2026-11-02
Previous EPS

: -0.04

Estimated EPS:

: -0.01

: 2026-11-02
Previous EPS

: -1.27

Estimated EPS:

: -0.05

Description
: Drug: pegtibatinase (TVT-058). Indication: Classical Homocystinuria (HCU). Timeline: 2H 2027. Travere’s pivotal Phase 3 HARMONY Study of pegtibatinase (TVT-058) in classical homocystinuria (HCU) is continuing enrollment, with topline data anticipated in 2H 2027.
: 2026-11-02
Previous EPS

: -0.1

Estimated EPS:

: 0.95

Description
: Drug: VOXZOGO (vosoritide). Indication: children with achondroplasia. Timeline: Feb. 28, 2027. BioMarin's supplemental NDA for VOXZOGO containing long-term safety and efficacy data from three ongoing studies, including adult height and additional outcomes beyond linear growth, is under FDA review with a PDUFA target action date of Feb. 28, 2027.
: 2026-11-02
Previous EPS

: -4.34

Estimated EPS:

: -1.07

Description
: Drug: darovasertib in combination with crizotinib. Indication: first-line HLA*A2-negative metastatic uveal melanoma (mUM). Timeline: second half of 2026. IDEAYA expects to complete the NDA filing for darovasertib plus crizotinib for first-line HLA*A2-negative metastatic uveal melanoma in the second half of 2026; the program will proceed under the FDA OCE Real-Time Oncology Review (RTOR) process.
: 2026-11-02
Previous EPS

: -0.35

Estimated EPS:

: -0.24

: 2026-11-02
Previous EPS

: 3.74

Estimated EPS:

: -0.54

: 2026-11-02
Previous EPS

: 1.06

Estimated EPS:

: 0.14

: 2026-11-02
Previous EPS

: 15.01

Estimated EPS:

: 3.96

: 2026-11-02
: 2026-11-02
: 2026-11-02
Previous EPS

: -1.93

Estimated EPS:

: -0.45

Description
: IND submission planned.
: 2026-11-02
Previous EPS

: -0.84

Estimated EPS:

: -0.2

Description
: Genelux Corporation is participating in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference where they may discuss upcoming clinical trial results and developments related to Olvi-Vec.
: 2026-11-02
Previous EPS

: 0.84

Estimated EPS:

: 0.22

: 2026-11-02
Previous EPS

: 15.68

Estimated EPS:

: 4.71

Description
: Drug: povetacicept. Indication: adults with IgA nephropathy (IgAN). Timeline: November 30, 2026. The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.
: 2026-11-18
Previous EPS

: -3.89

Description
: Drug: nebokitug (anti-CCL24 antibody). Indication: Rheumatoid arthritis (RA). Timeline: H1 2028. Topline readout of the nebokitug Phase 2 rheumatoid arthritis trial is expected in H1 2028. The precision-medicine study will use standard 12-week FDA RA endpoints and Scipher’s PrismRA® test to guide patient enrollment.
: 2026-11-18
Previous EPS

: 1.3

Estimated EPS:

: 0.38

: 2026-11-18
Previous EPS

: -0.09

: 2026-11-18
Previous EPS

: -0.72

: 2026-11-18
Previous EPS

: -0.92

Description
: Drug: iSCIB1+. Indication: advanced melanoma. Timeline: in the next 12 months. Further Progression Free Survival and Overall Survival data from the Phase 2 SCOPE study for iSCIB1+ expected to be released in the next 12 months.
: 2026-11-18
Previous EPS

: -0.07

Description
: Drug: IGC-AD1. Indication: agitation in Alzheimer's dementia. Timeline: fourth quarter of 2026. IGC-AD1, the lead candidate in the Phase 2 CALMA trial for agitation in Alzheimer's dementia; enrollment (168 participants randomized in the US and Canada) is complete, with topline results anticipated in the fourth quarter of 2026.
: 2026-11-18
: 2026-11-18
Previous EPS

: -8.37

: 2026-11-18
Previous EPS

: -1.38

Estimated EPS:

: -0.28

: 2026-11-19
Previous EPS

: -1.38

Description
: Drug: EVX-04 DNA vaccine. Indication: Acute myeloid leukemia (AML). Timeline: 2026-12-13. Evaxion will present new preclinical data for EVX-04, an off-the-shelf DNA therapeutic vaccine for acute myeloid leukemia, in a poster session (Poster #4310, Session 801) at the ASH Annual Meeting in New Orleans on December 13, 2026.
: 2026-11-19
Previous EPS

: -12.39

: 2026-11-19
Previous EPS

: -1.07

: 2026-11-23
Previous EPS

: -0.14

Estimated EPS:

: -0.07

: 2026-11-23
Previous EPS

: 5.11

Estimated EPS:

: 1.41

: 2026-11-24
: 2026-11-24
Previous EPS

: 4.09

Estimated EPS:

: 1.54

: 2026-11-24
Previous EPS

: -1.99

Estimated EPS:

: 0.2

: 2026-11-24
: 2026-11-24
Previous EPS

: -1.12

: 2026-11-24
Previous EPS

: -0.66

: 2026-11-26
Previous EPS

: -3.67

Estimated EPS:

: -0.06

: 2026-11-22
Previous EPS

: -2.52

: 2026-11-25
Previous EPS

: -1.15

Estimated EPS:

: -0.2